What's in Institut Jerome Lejeune's pipeline?

Institut Jerome Lejeune has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Institut Jerome Lejeune's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/institut-jerome-lejeune.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Institut Jerome Lejeune — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Institut Jerome Lejeune pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
thyroid hormone and folinic acid	thyroid hormone and folinic acid	phase 3	Hormone replacement and vitamin supplement combination	Thyroid hormone receptors (TR-α, TR-β); folate metabolism enzymes	Endocrinology / Neurodevelopmental disorders

Therapeutic area mix

Endocrinology / Neurodevelopmental disorders · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Institut Jerome Lejeune:

Cite this brief

Drug Landscape (2026). Institut Jerome Lejeune — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-jerome-lejeune. Accessed 2026-05-17.